Prosensa Looks To Take DMD Programs Forward, Remains Hopeful For Drisapersen
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CEO Schikan notes that despite GSK’s exit from drisapersen collaboration, the four-plus year partnership left his firm with the largest clinical database in the rare disorder. Next step is meeting with stakeholders to find a regulatory path forward for the Phase III exon-skipping compound.